<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01083667</url>
  </required_header>
  <id_info>
    <org_study_id>0903010259</org_study_id>
    <nct_id>NCT01083667</nct_id>
  </id_info>
  <brief_title>SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>Phase I/II Study of SOD1 Inhibition by Pyrimethamine in Familial ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Muscular Dystrophy Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study will be to evaluate the safety, tolerability and effect on SOD1
      levels by pyrimethamine in patients with familial amyotrophic lateral sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease causing relentlessly
      progressive weakness of the arms, legs and respiratory muscles that is uniformly fatal. There
      are approximately 30,000 patients living with ALS in the United States. There is no
      treatment. The cause is uncertain in most patients. However, 3% of patients (&lt; 1000 in
      number) have a familial form of ALS (FALS), phenotypically identical to the sporadic illness,
      that is caused by a mutation in the gene coding for the free radical scavenging enzyme
      copper/zinc superoxide dismutase (SOD1). Inserting the SOD1 mutant gene into mice causes them
      to develop a disease closely resembling ALS.

      Inhibiting expression of the SOD1 gene prevents animals from developing the disease.
      Increasing or decreasing the number of mutated genes proportionately speeds or slows the
      progression of the disease. Therefore, reducing SOD1 levels in patients with SOD1 associated
      FALS may be a promising therapeutic approach. Through an extensive in vitro screening program
      for medications having the ability to reduce SOD1 levels, several molecules that reduce SOD1
      protein levels are known. One of the most potent molecules is pyrimethamine, an FDA approved
      medication used for the treatment of malaria and toxoplasmosis. Pyrimethamine dramatically
      reduces SOD1 levels in mice and our preliminary studies show similar findings in humans. Our
      study's primary objective is to determine if familial ALS patients taking pyrimethamine will
      show a decline in SOD1 levels in the CSF by 15% or more. We will also determine if SOD1 and
      pyrimethamine are present in the blood and if the SOD-1 levels decline over the course of the
      study. We will also evaluate the safety and tolerability of pyrimethamine in patients with
      FALS. Secondary objectives will be to determine dose optimization for maximal SOD1 level
      reduction and tolerability of medication. We will also assess the feasibility of proceeding
      to phase II/III studies using pyrimethamine. Change in ALS-FRS, Appel ALS score and quality
      of life will also be measured. A clinical effect realized in patients with FALS associated
      with an SOD1 mutation may serve as an important foundation toward finding a treatment for
      sporadic ALS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in SOD1 CSF</measure>
    <time_frame>baseline, Visit 6 week 18, end of study</time_frame>
    <description>Reported change in mean SOD1 CSf from baseline to visit 6 (week 18) and end of study for all subjects who completed the measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appel ALS Score</measure>
    <time_frame>Week 0, 6, 18, and end of study</time_frame>
    <description>an objective and timed measurement of strength and function of subjects including muscle testing, respiratory function and fine motor function, all summed together for a total value, and is measured at baseline, visit 2, visit 6 and end of study. The scale ranges from 30 in a healthy person to to 164 in a maximally impaired person; an increase in score indicates progression and is expected in disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Familial Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Pyrimethamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label. Only one arm will receive the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrimethamine</intervention_name>
    <description>Open Label, dose escalating,</description>
    <arm_group_label>Pyrimethamine</arm_group_label>
    <other_name>Daraprim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with definite, probable, or laboratory supported probable ALS will be
             eligible.

               1. ALS diagnosed as probable, laboratory supported probable or definite according to
                  the World Federation of Neurology El Escorial criteria [Brooks et al. 2000]

               2. Age 18 or older

               3. Capable of providing informed consent and complying with trial procedures

               4. SOD1 mutation confirmation by study team

               5. Not taking Riluzole (Rilutek) or on a stable dose for 30 days

               6. Not taking Coenzyme QR10R or on a stable dose and brand for 30 days

               7. Absence of exclusion criteria

        Exclusion Criteria:

          1. History or evidence of malabsorption syndromes

          2. Exposure to any experimental agent within 30 days of onset of this protocol

          3. Women who are pregnant or planning to become pregnant

          4. Women of childbearing potential not practicing contraception

          5. Women who are breastfeeding

          6. Enrollment in another research study within 30 days of or during this trial

          7. Alcoholism

          8. Patients taking phenytoin (Dilantin) or other therapy affecting folate levels

          9. Dementia (MMSE &lt;22)

         10. Seizure disorder

         11. Folate deficiency

         12. Megaloblastic anemia

         13. Cardiovascular disorder/arrhythmia

         14. Impaired kidney function, defined as creatinine levels of 2.5 x ULN

         15. Impaired liver function, defined as AST or ALT of 3 X ULN

         16. Advanced ALS patients, defined as those with any of the following: forced vital
             capacity &lt;60% (use of BIPAP is allowed); tracheostomy; or mechanical ventilation

         17. Use of any of the following medications: cytosine, arabinoside, methotrexate,
             daunorubicin, sulfonamides, zidovudine, lorazepam, coumadin, sulfamethoxazole, and
             trimethoprim

         18. Patients taking Lithium within 30 days of or during this trial

         19. Incapable of providing informed consent and complying with trial procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dale J. Lange, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Special Surgery/Weill Cornell Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical Center/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Neurological Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit√§ts- und Rehabilitationskliniken Ulm</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milano Neurological Institute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umea University</name>
      <address>
        <city>Umea</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <results_first_submitted>February 17, 2017</results_first_submitted>
  <results_first_submitted_qc>May 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2017</results_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>Dr. Dale J. Lange</investigator_full_name>
    <investigator_title>Neurologist in Chief</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Familial ALS</keyword>
  <keyword>SOD1 Gene Mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient were recruited from all sites and referrals received from other physicians. Subjects also contacted sites from ClinicalTrials.gov posting</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pyrimethamine</title>
          <description>Open label. Only one arm will receive the intervention.
Pyrimethamine: Open Label, dose escalating,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32">enrolled</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22">22 completed to visit 9, the last visit on study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pyrimethamine</title>
          <description>Open label. Only one arm will receive the intervention.
Pyrimethamine: Open Label, dose escalating,</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>age of subjects enrolled</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="19" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>gender of subjects enrolled</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>enrollment of subjects in US and Europe</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in SOD1 CSF</title>
        <description>Reported change in mean SOD1 CSf from baseline to visit 6 (week 18) and end of study for all subjects who completed the measure</description>
        <time_frame>baseline, Visit 6 week 18, end of study</time_frame>
        <population>24 subjects completed up to visit 6 and 21 subjects for final study visit. Reported is the change in SOD1 CSF from baseline to week 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Pyrimethamine</title>
            <description>Open label. Only one arm will receive the intervention.
Pyrimethamine: Open Label, dose escalating,</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in SOD1 CSF</title>
          <description>Reported change in mean SOD1 CSf from baseline to visit 6 (week 18) and end of study for all subjects who completed the measure</description>
          <population>24 subjects completed up to visit 6 and 21 subjects for final study visit. Reported is the change in SOD1 CSF from baseline to week 36.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="3.4" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Appel ALS Score</title>
        <description>an objective and timed measurement of strength and function of subjects including muscle testing, respiratory function and fine motor function, all summed together for a total value, and is measured at baseline, visit 2, visit 6 and end of study. The scale ranges from 30 in a healthy person to to 164 in a maximally impaired person; an increase in score indicates progression and is expected in disease progression.</description>
        <time_frame>Week 0, 6, 18, and end of study</time_frame>
        <population>22 subjects completed to visit 9 and had a final score for Appel Score. Reported is the mean change from Baseline to week 36</population>
        <group_list>
          <group group_id="O1">
            <title>Pyrimethamine</title>
            <description>Open label. Only one arm will receive the intervention.
Pyrimethamine: Open Label, dose escalating,</description>
          </group>
        </group_list>
        <measure>
          <title>Appel ALS Score</title>
          <description>an objective and timed measurement of strength and function of subjects including muscle testing, respiratory function and fine motor function, all summed together for a total value, and is measured at baseline, visit 2, visit 6 and end of study. The scale ranges from 30 in a healthy person to to 164 in a maximally impaired person; an increase in score indicates progression and is expected in disease progression.</description>
          <population>22 subjects completed to visit 9 and had a final score for Appel Score. Reported is the mean change from Baseline to week 36</population>
          <units>units on a scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="12" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE's were collected over the course of the study and up to 30 days following the last dose taken.</time_frame>
      <desc>CTCAE version 4.0 was used to assess the severity of AE's experienced during the study. This uses a grading system (referring to the severity) to assess the AEs. The CTCAE v4.0 displays Grades 1-5 with unique clinical descriptions of severity for each AE based on this general guideline: G1 Mild AE, G2 Moderate AE, G3 Severe or medically significant but not immediately life-threatening, G4 Life-threatening, G5 Death related to AE.
SAE reporting per criteria od clinicaltrials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>Pyrimethamine</title>
          <description>Open label. Only one arm will receive the intervention.
Pyrimethamine: Open Label, dose escalating,</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Patient admitted to the hospital with pneumonia while on study, course complicated by discovery of a congenital esophageal fistula which was repaired, patient discharged home and continued on the study. The event was not related to study medication.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <description>URI infection and Pneumonia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>GI nausea</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <description>greater than 5% was recorded</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain following Spinal Tap</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>headache following spinal tap</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dale Lange</name_or_title>
      <organization>HSS/WCMC</organization>
      <phone>6467978917</phone>
      <email>langed@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

